Biogen Inc
BIIB
NASDAQ
Biotechnology
$209.83
USD
-0.82 (-0.39%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $31.05B
Volume 554.4K
Revenue
$10.03B
TTM
+0.3%
YoY
Gross Margin
74%
TTM
-1.9%
YoY
Net Income
$834.60M
TTM
-45.5%
YoY
Operating Cash Flow
$2.88B
TTM
+36.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2,645.5 | 2,534.7 | 2,279.4 | 2,477.8 | 2,736.0 |
YoY Growth | +7.3% | +2.8% | -7.1% | +1.9% | +3.4% |
Cost of Revenue | 605.0 | 674.4 | 495.5 | 661.0 | 776.9 |
Gross Profit | 2,040.5 | 1,860.3 | 1,783.9 | 1,816.8 | 1,959.1 |
Selling, General & Administrative | 583.8 | 594.8 | 682.5 | 607.3 | 709.7 |
Other Operating Expenses | 87.5 | 100.2 | 134.6 | 102.6 | 236.7 |
Total Operating Expenses | 1,247.8 | 1,268.9 | 1,685.5 | 1,419.4 | 1,808.2 |
Operating Income | 792.7 | 591.4 | 98.4 | 397.4 | 150.9 |
EBITDA | 999.5 | 806.6 | 329.7 | 609.7 | 554.9 |
Other Income / Expense | -8.4 | -34.1 | -154.4 | -19.7 | 38.5 |
Total Other Income / Expense | -48.7 | -34.1 | -154.4 | -19.7 | -18.5 |
Income Before Income Taxes | 744.0 | 557.3 | -56.0 | 377.7 | 132.4 |
Income Taxes | 109.2 | 90.8 | -7.1 | 58.2 | 34.9 |
Net Income | 634.8 | 466.5 | -48.9 | 319.5 | 97.5 |
Consolidated Net Income / Loss | 634.8 | 466.5 | -48.9 | 319.5 | 97.5 |
Net Income Attributable to Common Shareholders | 634.8 | 466.5 | -48.9 | 319.5 | 97.5 |
Basic EPS | $4.33 | $3.18 | -$0.33 | $2.17 | $0.66 |
Diluted EPS | $4.33 | $3.17 | -$0.33 | $2.15 | $0.66 |
Basic Shares Outstanding | 146.5M | 146.6M | 146.8M | 147.2M | 147.7M |
Diluted Shares Outstanding | 146.7M | 147.1M | 148.0M | 148.4M | 148.7M |